Organizations Report issue

This page summarizes information about the organizations (Orgs) that have contributed to the clinical-stage research and development of both innovator medicines as well as their generic equivalents. Please note the lead sponsor for a trial is the organization with responsibility for conducting the trial and reporting the information to ClinicalTrials.gov. Additional information on this page includes fundamental backgrounds of the organizations, the active pharmaceuticals under investigation, clinical trials, diseases investigated as well as mechanisms and targets explored. We identify the different types of sponsoring organizations regardless of whether these arise from the public (defined as academia, non-profits and foundations), the private sector (both public and private companies) and government.
Small molecule
(19420 orgs)
1822
Marketing Approval Rosengarten & Sons, Inc. quinine
Vaccine
(2397 orgs)
1890
NME Approval Humboldt University tuberculin
Animal product
(1554 orgs)
1915
NME Approval Rockefeller University anti-dysenteric serum
Allergen
(365 orgs)
1924
NDA Approval Jubilant Innovation Ltd. meadow fescue grass pollen allergen
Biological
(2300 orgs)
1924
NDA Approval Jubilant Innovation Ltd. mixed vespid venom protein
Botanical
(3118 orgs)
1950
NME Approval Irwin Neisler, & Company veratrum viride root
Peptide
(1555 orgs)
1968
Marketing Approval Monarch Pharmaceuticals gramicidin
Cell therapy
(3049 orgs)
1971
Phase 3 Trial Centro Oncologico de Excelencia corynebacterium granulosum p40
Recombinant protein
(3108 orgs)
1975
NDA Approval Serono lutropin alpha
mAb
(4015 orgs)
1980
Phase 1 Trial Johnson and Johnson muromonab cd3
Nucleic acid
(397 orgs)
1993
Phase 2 Trial National Cancer Institute (NCI) g4460
org_id earliest_year Sponsor Lead Sponsor Years Lead Sponsor Trials Total Trials Org Type
org_id earliest_year Sponsor NME Years NME Approvals Secondary NDAs Generics Approvals Org Type